Seraphina Therapeutics Achieves Major Growth Recognition

Author: Evelyn Baker Updated: 08-12-2025 11:32 AM

Seraphina Therapeutics Recognized in the Inc. 5000 List

Seraphina Therapeutics has made a significant mark in the business world by securing a spot at No. 177 on the prestigious Inc. 5000 list for the year 2025. This list is known for celebrating America’s fastest-growing private companies, showcasing their impressive growth over the past three years.

Record-Breaking Revenue Growth

With astounding three-year revenue growth reaching 3,031%, Seraphina Therapeutics has firmly established itself as a standout performer. Their innovative product, fatty15, a C15:0 longevity supplement, has propelled the company to the forefront of the health and wellness industry.

Achievements and Recognitions

Seraphina's remarkable journey to this accolade underscores their commitment to improving lives globally. Dr. Eric Venn-Watson, co-founder and co-CEO, expressed pride in the company’s accomplishments, highlighting their mission to make a meaningful impact on health and wellness.

The Journey of fatty15

Launched in January 2021, fatty15 not only stands out as a first-of-its-kind supplement but also boasts a remarkable customer retention rate of 95%. With over 100,000 active subscribers, it clearly resonates with its audience, demonstrating a strong demand for its health benefits.

Community Impact and Job Creation

The Inc. 5000 list reflects a broader economic trend, with its honorees contributing to the creation of approximately 48,678 jobs in the U.S. over the past three years. The median revenue growth rate among the top 500 businesses is 1,552%, showcasing resilience even amid economic challenges.

Upcoming Celebrations and Future Prospects

Seraphina Therapeutics is set to be honored at the upcoming Inc. 5000 Conference & Gala, which will celebrate the achievements of these remarkable companies. This gathering not only highlights their successes but also reinforces the entrepreneurial spirit that powers the U.S. economy.

Continued Expansion

As Seraphina Therapeutics continues to innovate and expand its product lines, their commitment to enhancing overall health remains unwavering. The company's growth trajectory positions it as a leader in the wellness sector, fundamentally changing how consumers view nutritional supplements.

Methodology for Selection

The Inc. 5000 listings rank companies based on percentage revenue growth over a specific period. To qualify, businesses must be U.S.-based, privately held, and show consistent growth patterns, ensuring that only the best are recognized.

About Seraphina Therapeutics

Seraphina Therapeutics is dedicated to developing innovative health solutions to improve quality of life. The pioneering work by its founders reflects a deep commitment to health and wellness that resonates with many. With ambitious plans for the future, Seraphina Therapeutics is set to make waves in the health industry.

Frequently Asked Questions

What is the Inc. 5000 list?

The Inc. 5000 list ranks the fastest-growing private companies in America based on their revenue growth over three years.

What product did Seraphina Therapeutics launch?

Seraphina Therapeutics launched fatty15, a C15:0 longevity supplement that has contributed significantly to the company’s growth.

What are Seraphina's future plans?

Seraphina Therapeutics aims to expand its product lines and continue to enhance health solutions for consumers worldwide.

How many jobs have Inc. 5000 companies created?

Companies on the Inc. 5000 list have collectively added over 48,678 jobs to the U.S. economy in the past three years.

What is unique about fatty15?

Fatty15 is noted for its high customer retention rate and effectiveness, making it a unique product in the longevity supplement market.

About The Author

Greetings, I'm 32-year-old author and financial specialist Evelyn Baker. My introduction into the financial industry started with an economics degree and continued with a wealth of experience in wealth management and financial consulting. My great passion over the years has been assisting people and companies in making wise, well-informed decisions to reach their financial objectives.

My goal with writing is to simplify difficult financial ideas into understandable, doable guidance. My goal in writing many books and articles is to make personal finance understandable to everyone, irrespective of their experience or background. I want to give readers the information they need to take charge of their financial futures, from investing and retirement planning to budgeting and saving.

Along with my writing, I lead webinars and workshops where I provide doable advice and methods for achieving financial success. To reach a larger audience, I also frequently contribute to financial blogs and publications. My method is always to offer doable, real-world guidance that can actually improve people's lives.

Aside from my job, I like to cook, travel, and experience other cultures. I work hard to apply my belief in the value of a balanced life to my financial counsel. My goal in working is to encourage and enable people to succeed financially so they may lead the best lives possible.

Contact Evelyn Baker privately here. Or send an email with ATTN: Evelyn Baker as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.